Company: RGBP
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022884
Chunk: 24

Company: Regen BioPharma Inc
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 4
Chunk 24
---
Item
4. Controls and Procedures.

Evaluation
of Disclosure Controls and Procedures

As
of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation
of David Koos, who is the Company’s Principal Executive Officer and Principal Financial Officer of the effectiveness of the design
and operation of the Company’s disclosure controls and procedures. The Company’s disclosure controls and procedures are designed
to provide a reasonable level of assurance of achieving the Company’s disclosure control objectives. The Company’s Principal
Executive Officer and Principal Financial Officer have concluded that the Company’s disclosure controls and procedures were ineffective
at this reasonable assurance level as of the period covered.

Changes
in Internal Controls over Financial Reporting

In
connection with the evaluation of the Company’s internal controls during the period commencing on April 1, 2025 and ending on June
30, 2025, David Koos, who serves as the Company’s Principal Executive Officer, Principal Financial Officer has determined that
there were no changes to the Company’s internal controls over financial reporting that have been materially affected, or is reasonably
likely to materially effect, the Company’s internal controls over financial reporting.

  25  

PART
II - OTHER INFORMATION

Item
1. Legal Proceedings.